


## PHARMACEUTICAL 2022

## **BIOXYTRAN INC** Rank 465 of 475





## PHARMACEUTICAL 2022

## **BIOXYTRAN INC** Rank 465 of 475

The relative strengths and weaknesses of BIOXYTRAN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOXYTRAN INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 2,130% points. The greatest weakness of BIOXYTRAN INC is the variable Assets, Current, reducing the Economic Capital Ratio by 859% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,287%, being 1,011% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	72
Cost of Goods Sold	0
Intangible Assets	47
Liabilities, Current	3,277
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	583
Other Liabilities	0
Other Net Income	-314
Property and Equipment	0
Research and Development	2,014
Revenues	0
Selling, General and Administrative Expense	1,618

Output Variable	Value in 1000 USD
Assets	119
Liabilities	3,277
Expenses	4,214
Stockholders Equity	-3,158
Net Income	-4,528
Comprehensive Net Income	-4,528
Economic Capital Ratio	-1,287%